Zevra Therapeutics(US:ZVRA) Globenewswire·2025-03-11 20:05Core Insights - Zevra Therapeutics reported FY 2024 net revenue of $23.6 million, with Q4 2024 net revenue of $12.0 million, driven by the commercial launch of MIPLYFFA [1][11] - The company entered into an asset purchase agreement for the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million [6] - Zevra's strategic plan focuses on four pillars: commercial excellence, pipeline and innovation, talent and culture, and corporate foundation [2] Financial Highlights - Q4 2024 net revenue breakdown: $10.1 million from MIPLYFFA, $0.1 million from OLPRUVA, $1.1 million in net reimbursements from the French EAP for arimoclomol, and $0.7 million in royalties under the AZSTARYS license agreement [11] - Operating expenses for Q4 2024 were $24.5 million, including $4.0 million in non-cash stock compensation [10] - FY 2024 net loss was $105.5 million, or $2.28 per share, compared to a net loss of $46.0 million, or $1.30 per share in FY 2023 [12][37] Commercial Launch and Pipeline - MIPLYFFA was launched immediately after FDA approval on September 20, 2024, with U.S. commercial availability starting on November 21, 2024 [8] - As of December 31, 2024, Zevra received 109 total prescription enrollment forms for MIPLYFFA [8] - The company is targeting regulatory approval in the EU for MIPLYFFA, with a Marketing Authorisation Application filing planned for the second half of 2025 [8] Talent and Culture - In Q4 2024, Zevra consolidated its development and scientific functions under the leadership of its Chief Medical Officer, Adrian Quartel, M.D. [5] Corporate Foundation - The sale of the PRV is expected to provide net proceeds of $148.3 million after fees, enhancing the company's cash position [10][11] - As of December 31, 2024, Zevra had cash, cash equivalents, and investments totaling $75.5 million, extending its cash runway into 2029 [11]